Citrine Capital’s Gilead Sciences GILD Stock Holding History

Citrine Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,516	Closed	-$211K	–	63
2026 Q1	$211K	Buy	+1,516	New	+$212K	0.09%	55

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citrine Capital's GILD Position: Q2 2026 in Review

Citrine Capital sold out of Gilead Sciences (GILD) in Q2 2026, closing a stake of 1,516 shares — an estimated $211K sold.

Citrine Capital first reported a position in GILD in Q1 2026 and held it in 1 quarter. The position peaked at $211K in Q1 2026. 2,261 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Citrine Capital reported no remaining Gilead Sciences position as of Q2 2026 after selling out during the quarter.
Citrine Capital sold 1,516 Gilead Sciences shares in Q2 2026, an estimated $211K.
Citrine Capital first reported a position in Gilead Sciences in Q1 2026 and held it in 1 quarter.
Citrine Capital's Gilead Sciences position peaked at $211K in Q1 2026.
2,261 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Citrine Capital's 13F filing for Q2 2026, filed 23 Jul 2026.